CellVoyant launches new online predictive cell analytics platform to fast-track drug development
6 Jan 2026
CellVoyant, an AI-first biotech based in Bristol, UK, has launched FateView™, the first online predictive cell analytics platform designed to help cell-based therapeutic drug developers reduce costs, accelerate and scale cell analyses, and make faster, more confident decisions throughout the drug development process.
CellVoyant’s mission is for its technology to help make cell-based therapeutic products more affordable and readily accessible to patients that need them most.
In the case of cell therapy products 4% of cell therapy assets fail after the two-year point in development, each costing ~$50M. For each clinical cell line asset, cell therapy developers spend up to $600K just in clone selection and well over ~$1M for process optimization. This makes it critical that scientists have solutions in place to increase their success rates in cell development, remove cell development and manufacturing bottlenecks, and work with the most viable and best quality cells as soon as possible.
FateView™ combines AI, computer vision and label-free imaging to give scientists instant insights and predictions into the behavior of cells without needing to disaggregate or destroy cells, contrary to what is required by most conventional methods. It allows scientists to better control and accelerate the development and manufacturing of cell-based analyses and processes, enabling to save potentially millions in R&D and manufacturing costs.
Technology breakthrough provides instant insights
Traditional cell assessment methods rely on frequent manual (i.e. visual) inspection and on carrying out multiple destructive assays with cells. Such methods are time-intensive, subjective and prone to error, and testing multiple samples simultaneously often leads to high waste and cost, with cells most often needing to be destroyed along the way.
FateView™ transforms lengthy manual workflows into a rapid, remote, and scalable process — replacing days of manual microscopy work with a single uploaded image.
Using only standard white-light microscopy images, FateView™ can enable:
- Quickly identify complex patterns of marker expression across many cells and samples — for example, turning a standard 48-hour immunofluorescence experiment into an online result in under a minute, cutting analysis time and costs by around 99%.
- Predict important marker expression for individual cells without needing to perform immunohistochemistry or other time-consuming staining procedures.
- Forecasting cell behavior hours or days ahead, including predicting how well cells will differentiate into intended lineages.
All without having to sacrifice samples, which had never been possible until now.
CellVoyant CEO & Founder, Rafael Carazo Salas, said, "With FateView™, we’re offering a new, highly innovative way by giving every researcher – from labs to manufacturing settings – the ability to snap images, 'visually' inspect cells instantly with AI and instantaneously obtain quantitative actionable readouts that would otherwise require lengthy and costly assays, while keeping cells intact. This enables researchers and drug developers to make critical decisions much faster and scalably across batches and samples."
"Our vision is to make predictive cell analytics accessible instantly and online, powering decisions that happen in labs every day all over the world. This will help to accelerate the development and ultimately the delivery of breakthrough therapies to those who need them most,” he added.